MEDPLUS Medplus Health Services Q2 FY26 results (Jul–Sep 2025) and concall
Medplus Health reported a robust Q2 FY26, with consolidated revenue of INR16,793 million and an operating EBITDA margin of 5.3%. The diagnostics segment demonstrated significant growth in both revenue and profitability. The company continued its network expansion, adding 117 net stores, and saw its same-store sales growth turn positive at 2.2%. Management expressed confidence in achieving annual store addition targets and outlined plans for private label growth re-acceleration and SSSG improvement.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 32.1%, net profit up 100.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 156 | 177 | 202 | 184 | 206 +32% |
| EBITDA | 17 | 19 | 24 | 24 | 27 +59% |
| Net profit | 8 | 9 | 14 | 14 | 16 +100% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
